Director John M. Fluke Jr. receives 28,000-share option grant at LeonaBio (LONA)

Rhea-AI Filing Summary

LeonaBio, Inc. director John M. Fluke Jr. received an option grant covering 28,000 shares of common stock. The stock option has an exercise price of $9.54 per share and expires on April 8, 2036.

The award was granted as compensation (not an open‑market purchase) and vests in equal monthly installments over 24 months from the grant date, contingent on Mr. Fluke continuing to serve as a Service Provider under LeonaBio’s 2026 Equity Incentive Plan. Following this award, he holds options for 28,000 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider FLUKE JOHN M JR

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	28,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 28,000 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Option size: 28,000 shares Exercise price: $9.54 per share Expiration date: April 8, 2036 +2 more

5 metrics

Option size 28,000 shares Stock Option (Right to Buy) granted to director

Exercise price $9.54 per share Conversion or exercise price of option

Expiration date April 8, 2036 Option term end date

Vesting period 24 months Monthly vesting over two years from grant date

Shares following transaction 28,000 options Total derivative shares held after grant

Key Terms

Stock Option (Right to Buy), 2026 Equity Incentive Plan, Service Provider, vesting

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

2026 Equity Incentive Plan financial

"as defined in the Issuer's 2026 Equity Incentive Plan"

Service Provider financial

"subject to the optionee continuing to be a Service Provider"

vesting financial

"scheduled to vest monthly over a term of 24 months"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FLUKE JOHN M JR

(Last) (First) (Middle)

C/O LEONABIO, INC.

18706 NORTH CREEK PARKWAY, SUITE 104

(Street)

BOTHELL WASHINGTON 98011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LeonaBio, Inc. [ LONA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.54	04/09/2026		A		28,000		(1)	04/08/2036	Common Stock	28,000	$0	28,000	D

Explanation of Responses:

1. The shares subject to the option shall be scheduled to vest monthly over a term of 24 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.

	/s/ Mark Worthington, Attorney in fact for John M. Fluke, Jr.	04/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did LeonaBio (LONA) director John M. Fluke Jr. report on this Form 4?

He reported receiving a stock option grant for 28,000 shares of LeonaBio common stock. The option was awarded as compensation, not through an open-market purchase, and represents his reported derivative holdings following this transaction.

What are the key terms of John M. Fluke Jr.’s LeonaBio (LONA) stock option?

The option covers 28,000 underlying common shares at an exercise price of $9.54 per share. It expires on April 8, 2036, giving the director a long-dated right to buy shares at that fixed price if the option becomes vested.

How does the LeonaBio (LONA) stock option granted to John M. Fluke Jr. vest?

The option vests in monthly installments over 24 months from the grant date. Each month, a portion becomes exercisable as long as he continues to qualify as a Service Provider under LeonaBio’s 2026 Equity Incentive Plan through the applicable vesting dates.

Did John M. Fluke Jr. buy or sell any LeonaBio (LONA) shares in the market?

No open-market buy or sell transactions were reported. The Form 4 shows only a compensation-related stock option grant coded as “A,” meaning a grant or award acquisition, not a purchase or sale on a stock exchange.

What is John M. Fluke Jr.’s reported LeonaBio (LONA) option position after this filing?

After this transaction, he is reported as directly holding options for 28,000 underlying shares of LeonaBio common stock. The filing does not list additional derivative positions, indicating this grant constitutes his reported option holdings in this particular report.